|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, the Lmdd-MPFG vaccine activates the NF-κB pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway.
|
31659256 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR2 promotes cell cycle arrest by regulating the tumor suppressors p53-p21<sup>CIP1</sup>, p16<sup>INK4a</sup>, and p15<sup>INK4b</sup> and regulates the SASP through the induction of the acute-phase serum amyloids A1 and A2 (A-SAAs) that, in turn, function as the damage-associated molecular patterns (DAMPs) signaling through TLR2 in OIS.
|
31183403 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR2 was positively correlated with tumor grade (P < 0.05).
|
30898699 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, serum TLR2 levels might depend more on normal colorectal mucosa contributions than on tumor tissue contributions.
|
31132191 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we report the design of a new, safe, and specific TLR2 agonist that can generate macrophages with strong anti-tumor potential in mice.
|
31118418 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In esophageal cancer patients, mRNA expressions of TLR-2, TLR-4 and TLR-7, and protein concentrations of all TLRs were significantly higher in tumor than in control tissue (p < 0.05).
|
29968427 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that TLR2 and adenosine receptor agonists, known to be present in the tumor microenvironment, may contribute to OSCC progression in part via direct effects on the ERK1/2 pathway in squamous carcinoma cells.
|
29467931 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Naive CD4<sup>+</sup> T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.
|
29212908 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
|
30541631 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TLR2-mediated regulation of these anti-apoptotic and tumor suppressor genes was also supported by their increased and reduced expression, respectively, in two independent genetic GC mouse models (gp130<sup>F/F</sup> and Gan) characterized by high tumor TLR2 expression.
|
28481875 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor proliferation and growth as well as the number of tumor-associated neutrophils was significantly decreased in IL-17C<sup>-/-</sup> and TLR-2/4<sup>-/-</sup> mice exposed to NTHi.
|
28346430 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show that TLR2 signaling in CD11b<sup>+</sup>Ly6G<sup>-</sup>Ly6C<sup>high</sup> monocytic MDSCs (M-MDSCs), but not CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup> granulocytic MDSCs (G-MDSCs), enhances their immunosuppressive activity, thereby limiting anti-tumor T cell responses induced by TLR2-activated dendritic cells (DCs). iNOS induction was critical for Pam2CSK4-enhanced T cell suppression by M-MDSCs. iNOS was expressed in M-MDSC-derived macrophages, but not undifferentiated M-MDSCs, in cocultures with CD8<sup>+</sup> T cells, CD11c<sup>+</sup> DCs, antigen peptide and Pam2CSK4.
|
29296526 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results of multivariate analysis show that DSS was significantly associated with each of the following factors: TLR ≥ 2 (HR, 2.46; P = 0.044), PIVKA-II ≥ 100mAU/mL (HR, 5.11; P = 0.037), tumor stage (HR, 3.01; P < 0.001), and surgery for initial treatment (HR, 0.04; P < 0.001).
|
27941378 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found that expression of Tlr2 and its coreceptor Cd14 was induced in tumor epithelial cells in Gan mice, which was suppressed by the disruption of Myd88.
|
26888865 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further large-scale and functional studies are needed to confirm the role of TLR2 gene polymorphisms in HPV-related cervical neoplasia.
|
26988751 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also studied TLR2 and TLR expression at the protein and messenger RNA (mRNA) level in tumor and non-tumor tissue in patients with HCC (n = 95), finding that TLR2 and 4 are increased in HCC tumor tissue and that the expression of TLR2 correlates with clinicopathologic features of HCC.
|
27492456 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we analyzed the effect observed upon combining the TLR2 agonist, peptidoglycan (PGN), with radiation therapy on tumors as well as intestinal tissue, both in vitro and in vivo.
|
27708223 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to qRT-PCR data, expression levels of the endoplasmic reticulum-nuclei-1 (ERN1), Toll-like receptor 2 (TLR2), and human IFN regulatory factor 5 (IRF5) tumor suppressor genes elevated 2.05-, 2.08-, and 2.3-fold by ZA, respectively, in U87MG cells.
|
26646564 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present case control study was conducted to investigate the association between tumour suppressor gene TP53 codon 72 polymorphism and innate immune pathway gene TLR2∆22 (-196-174) polymorphism with BC in females of NER of India for the identification of novel biomarker of BC.
|
26188904 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TLR2 mRNA expression was increased in tumor tissue (RQ = 2.36) when compared to adjacent normal tissue (RQ = 1; P < 0.0001), whereas the TLR4 mRNA showed a basal expression (RQ = 0.74 vs RQ = 1, P = 0.452).
|
26167073 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytoplasmic TLR 2 expression correlated with small tumor size, while nuclear TLR 2 and TLR 5 expressions with larger tumors.
|
25862837 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor-suppressive function of Hic1 in colon is related to its inhibitory action on proproliferative signaling mediated by the Tlr2 receptor present on tumor cells.
|
25934696 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deletion of MYD88 or TLR2 in the intestinal epithelium markedly reduces DSS-induced colitis regeneration and spontaneous tumour development in mice.
|
25362351 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of TLR2 performed similar effects with miR-154 overexpression on CRC cells, and overexpression of TLR2 could significantly reverse the tumor suppressive effects of miR-154 on CRC cells.
|
24242044 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified 25 significantly mutated genes, including known drivers such as ataxia-telangectasia mutated (ATM), cyclin D1 (CCND1), and the tumor suppressor TP53; mutated genes encoding the anti-apoptotic protein BIRC3 and Toll-like receptor 2 (TLR2); and the chromatin modifiers WHSC1, MLL2, and MEF2B.
|
24145436 |
2013 |